Vasopore, Inc. — SEC Form D Filing

Vasopore, Inc. filed an SEC Form D on October 28, 2026, reporting $1.10M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
October 28, 2026
Amount reported
$1.10M
Round stage
Seed
Industry
Medical Devices
Website
https://www.vasopore.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with vascular disease need safer, more effective, and durable minimally invasive treatment options.

Solution

Vasopore is developing an active intravascular drug delivery platform to enable safer, more durable, and more effective minimally invasive therapies.

Why now

Growing demand for targeted, device-based local pharmacotherapy to avoid systemic toxicity and improve outcomes in complex vascular interventions.

Verdict

This cleared because the multi-billion-dollar exits of drug-coated balloons and intravascular lithotripsy proved strategic acquirers pay massive premiums for interventional catheter upgrades, not because active drug delivery had been mechanically or clinically de-risked. Investors implicitly bet that active elution solves the acute drug-loss and tissue-penetration ceilings of passive balloons without adding deliverability friction in tortuous vessels. What capped upside was standard medtech capital intensity: a sub-two-million-dollar seed barely finances bench validation, exposing early equity to crushing dilution across subsequent clinical trials and PMA-track timelines.

Source: SEC EDGAR Form D filing